purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation axsm earnings call period ending december image source motley fool axsome therapeutic axsm q earnings callfeb etcontents prepared remark question answer call participant prepared remark operatorhello welcome axsome therapeutic fourthquarter fullyear conference call webcast operator instruction reminder conference recorded pleasure turn call chief operating officer mark jacobson please go ahead sirmark jacobson chief operating officer good morning thank joining u today conference call morning issued earnings press release providing corporate update detail company financial result fourth quarter full year release crossed wire short time ago available website axsomecom today call making certain forwardlooking statement statement may include statement regarding among thing efficacy safety intended utilization investigational agent clinical nonclinical plan plan present report additional data anticipated conduct source future clinical trial regulatory plan future research development plan commercial plan regarding sunosi auvelity pipeline product revenue projection possible intended use cash investment forwardlooking statement based current information assumption expectation subject change involve risk uncertainty may cause actual result differ materially contained forwardlooking statement risk described periodic filing made security exchange commission including quarterly annual report cautioned place undue reliance forwardlooking statement made today date company disclaims obligation update statementsjoining call today dr herriot tabuteau chief executive officer nick pizzie chief financial officer ari maizel executive vice president head commercial herriot provide overview company progress made fourth quarter well key upcoming milestone following herriot nick review financial result ari provide commercial update open line question question taken order received turn call herriot herriot tabuteau chief executive officer thank mark good morning everyone thank joining axsome therapeutic fourthquarter yearend financial result business update conference call another strong year axsome built focused commercial execution firstinclass marketed product continued advancement expansion industryleading neuroscience pipeline first full year commercial company auvelity firstinclass oral nmda receptor antagonist sigma receptor agonist depression sunosi dnri taar agonist excessive daytime sleepiness generated combined net product revenue approximately million expect continued revenue growth aided completed sale force expansion auvelity increasing awareness differentiated product later call nick provide detail quarterly financials ari provide additional information commercial performance innovative development pipeline also progressed expanded made solid progress preparation ndas ax migraine ax fibromyalgia advanced phase trial ax narcolepsy ax alzheimers disease agitation initiated phase trial program solriamfetol adhd announced three additional new indication solriamfetol progress position u deliver multiple potentially valuedriving milestone throughout provide brief update industryleading neuroscience pipeline expected milestone starting two ndastate product ax acute treatment migraine track nda resubmission first half nda submission ax management fibromyalgia also tracking submission second quarter moving latestage clinical program completed enrollment phase symphony trial ax treatment narcolepsy track report topline result symphony first quarter ax phase advance trial treatment alzheimers disease agitation tracking completion second half based anticipated enrollment trend recent treatment market dynamic turning solriamfetol active molecule sunosi december held investor day event physician expert provided scientific clinical rationale underlying exploration solriamfetol new target indication including major depressive disorder binge eating disorder shift work disorder expect initiate phase trial indication first quarter new trial complement ongoing phase focus trial solriamfetol adult adhd focus tracking topline result second half overall development portfolio encompasses five innovative latestage patentprotected product candidate serious psychiatric neurologic condition successfully developed investigational medicine potential transform treatment landscape serious difficulttotreat cns disorder affect million people yous alone turn call nick provide detail financial performancenick pizzie chief financial officer thank herriot good morning today discus fourthquarter fullyear result provide financial guidance total product revenue million million fourth quarter full year representing yearoveryear growth respectively consisted net product sale million million fourth quarter full year royalty revenue million respectively total product revenue comparable period million million total revenue full year million includes license revenue million outlicensing sunosi certain exyous territory auvelity net product sale million million fourth quarter full year respectively representing first full year commercialization auvelity auvelity launched october th yous net sale million fourth quarter sunosi net product revenue million million fourth quarter full year representing yearoveryear growth respectively consisting million million net product sale million royalty revenue associated sunosi sale outlicensed territory respectively sunosi net sale comparable period million million total sunosi revenue full year million includes license revenue million outlicensing sunosi certain exyous territory total cost revenue million million fourth quarter full year total cost revenue comparable period million million total cost revenue full year included onetime cost million associated revenue received outlicensing sunosi certain exyous territory research development expense million million fourth quarter full year respectively compared million million comparable period increase primarily related focus trial solriamfetol adhd advancement ongoing trial ax ax manufacturing cost associated anticipated ndas ax ax postmarketing commitment auvelity sunosi higher personnel cost including noncash stock based compensation selling general administrative expense million million fourth quarter full year respectively compared million million comparable period increase primarily related commercialization activity auvelity sunosi including sale force marketing expense higher personnel cost related organizational growth including noncash stock based compensation net loss fourth quarter million per share compared net loss million per share comparable period net loss fourth quarter includes million noncash charge comprised million acquisitionrelated contingent consideration expense reflecting updated sale projection recently announced new indication solriamfetol million noncash stock based compensation expense million noncash intangible asset amortization net loss million per share full year compared net loss million per share full year net loss full year includes total noncash charge million includes million stock compensation expense million fair value contingent consideration expense million intangible amortization compared million million million respectively full year auvelity sunosi gtn discount q approximately q typically negative seasonality effect gtn reminder gtn discount auvelity q high upper mid sunosi due seasonal q gtn dynamic would therefore expect similar gtn q product ended million cash cash equivalent compared million december st believe current cash balance sufficient fund anticipated operation cash flow positivity based current operating plan would like turn call ari provide commercial updateari maizel executive vice president head commercial thank nick axsome completed first full year commercial company delivering strong performance onmarket product starting auvelity fourth quarter approximately prescription written auvelity representing quarteroverquarter growth performance contrast decline overall antidepressant market period additionally nearly new patient started auvelity quarter bringing total number unique patient treated auvelity since launch approximately fourth quarter firsttime auvelity prescribers activated sale team increasing cumulative total number prescribers since launch nearly payer coverage stable q auvelity remains accessible patient representing approximately covered life continue progress conversation major plan pbms across channel pursue access improvement patient auvelity performance quarter primarily driven specialist psychiatry practice psychiatry md nurse practitioner physician assistant nppas contributing robust growth quarter course addition observed meaningful traction within primary care segment among md nppas early impact recent sale force expansion began take hold increased call activity primary care office recent survey provider psychiatry primary care treat significant proportion depression patient key driver auvelity prescribing cited respondent include rapid onset action low impact weight gain sexual dysfunction addition adopter note positive impact auvelity demonstrated daytoday patient functioning improvement patient perception quality life axsome established strong commercial foundation support continued auvelity growth approximately sale representative calling healthcare provider continued investment industryleading digitalcentric commercialization platform well positioned accelerate education awareness objective across predominant depression treater yous enhanced brand story created augment provider perception auvelity anchored auvelitys key attribute auvelity rapidacting antidepressant work fast last rapid symptom improvement observed week one substantial symptom improvement observed week two sustained substantial symptom improvement observed week six auvelity wellestablished safety tolerability profile includes low impact weight sexual dysfunction risk movement disorder extrapyramidal symptom auvelity oral antidepressant modulates glutamatergic monoaminergic pathway key point consideration role glutamate depression increasingly understood accepted across clinician landscape optimistic auvelitys growth prospect longterm blockbuster potential transitioning sunosi total prescription representing sequential quarterly growth growth versus q approximately new patient started sunosi treatment quarter bringing total number unique patient treated sunosi since launch although excessive daytime sleepiness smaller market limited prescriber base continue activate new prescribers including fourth quarter alone total cumulative prescriber base since launch field team focused communicating needed urgency treat excessive daytime sleepiness symptom obstructive sleep apnea narcolepsy disproportionate focus nearly active weekly prescribers space payer coverage sunosi consistent q total life covered across channel recent survey sunosi adopter key attribute driving demand product cited respondent include significant sustained impact epworth sleepiness scale marketleading nineplus hour wakefulness observed phase clinical trial significant improvement patientreported outcome week proud commercial effort sunosi expect continued growth closing axsome delivered compelling commercial performance q optimization commercial infrastructure took shape completed first full year commercial company anecdotal feedback provider patient continues reinforce belief auvelity sunosi unique differentiated treatment option respective indication support growing confidence axsome reshaping treatment landscape cns condition turn call back mark qamark jacobson chief operating officer thank ari operator may please first question question answer operatorthank conducting questionandanswer session operator instruction first question today coming leonid timashev rbc capital market line liveleonid timashev rbc capital market analyst thanks taking question maybe start question advance readout guess maybe provide little bit color drove slip time line guess driving slower recruitment reflection potential market opportunity risk trial integrity especially standard care evolves thanksherriot tabuteau chief executive officer well thank question think second part question evolving nature standard care really driving indication really excited want take account recent launch brexpiprazole potential impact enrollment reminder brexpiprazole first drug approved indication internal analytics team monitoring closely prescription trend seen clear inflection prescribing attribute new indication revised guidance incorporates new information said confident able deliver data year ari comment evolving treated landscape brexari maizel executive vice president head commercial yeah would say related brexpiprazole increase seeing substantial increase across medicare channel tie directly ada indication think also really positive news ax clearly significant unmet treatment need give u great confidence future axsleonid timashev rbc capital market analyst got thank youoperatorthank next question today coming charles duncan cantor fitzgerald line livecharles duncan cantor fitzgerald analyst good morning herriot team congrats great year commercialization want follow question ax first regard commercial performance auvelity wondering provide sense persistence know may little bit long mentioned branding fast last term activity wondering see term refill patient staying drugherriot tabuteau chief executive officer thanks question charles still little early share information persistency adherence say feedback receiving patient clinician suggest clinical profile phase holding real world expect generate additional data future suffice say seeing real world reflective phase clinical trial resultscharles duncan cantor fitzgerald analyst ok helpful could follow last question regarding ax advance wondering changed perspective probability success given otsukas data recently also term openlabel extension patient enrolling appear going maybe yes kind broadlyherriot tabuteau chief executive officer yes thanks question charles regard otsuka readout think meaningful read product watch data readout development space potential learning clinical development however think best data look thinking potential ax alzheimers disease agitation data generated product reminder completed two phase trial placebocontrolled positive result think information relevant information molecule take one step actually look product different molecule entirely avp reminder deuteriummodified dextromethorphan whereas ax operates nondeuteriummodified dextromethorphan inhibitor also different use aminoketone use quinidine different relates openlabel safety extension trial going well vast majority patient rolling advance trial opting go openlabel safety extension think good indicator caregiver thinking productcharles duncan cantor fitzgerald analyst ok good thanks added color herriot hop back queueoperatorthank next question coming ash verma ubs line liveash verma ubs analyst thanks taking question two ad agitation maybe advance study trying recruit naive patient treatment want kind exclude anyone started therapy rexulti first one second like fast forwarding assume would come market would need primarily focus longterm care facility lot patient broadly reside curious type sale footprint might require versus think bcc platform kind like footprint thanksherriot tabuteau chief executive officer thank question answer yes recruiting primarily naive patient would want exclude folk rexulti obvious reason revised guidance take account potential impact losing patient patient treatment option approved term longterm care facility study thus far conducted community setting think majority patient reside indication one thing excited relates profile ax alzheimers disease agitation could potentially keep patient longterm care facility word keep home loved onesoperatorthank next question coming joon lee truist security line liveasim rana truist security analyst good morning asim joon thanks taking question wondering could comment breakdown patient auvelity currently around percent first line also want clarify expanded sale force fully online comment think current trx trend reflective full sale force thank youherriot tabuteau chief executive officer well thanks turn ariari maizel executive vice president head commercial hi thanks question seeing meaningful improvement term earlier line treatment course saw meaningful increase first second line treatment every quarter today roughly patient receiving auvelity first second line setting expect trend continue time regarding sale force expansion question fully complete expansion hired additional representative end last year completed training january year starting see meaningful impact term call activity particular seeing increase proportionally call primary care segment would expect trx nbrx trend continue increase course year ramp beginning q detail come pleased increased field force effort post expansionasim rana truist security analyst thank youoperatorthank next question coming jason gerberry bank america line livejason gerberry bank america merrill lynch analyst hey guy good morning thanks taking question wanted follow ada enrollment dynamic rexulti guess look growth brand trx basis inflection seem obvious wondering looking different metric gauge inflection know patient enrollment form claim given massive market little surprised know given trx move seen characterized inflection expectation still would get long term safety efficacy data second half would able file second half wondering filing timeline still track thanksherriot tabuteau chief executive officer thanks question given guidance filing going determined completion longterm safety extension trial gain factor regard seeing internal analytics team rexulti turn ariari maizel executive vice president head commercial yes thanks jason suggestion looking claimsbased data payer channel observation brexpiprazole increasing significantly within medicare channel attribute growth ada indication toojason gerberry bank america merrill lynch analyst ok thank youoperatorthanks next question coming david amsellem piper sandler line livedavid amsellem piper sandler analyst hey thanks couple first ad agitation talk potential branding differently auvelity pricing differently given medicare part market obviously different depression landscape number number couple reboxetine one talk timeline nda gating factor beyond study nda filing narcolepsy cataplexy thinking pricing market got one end spectrum pitolisant got end spectrum solriamfetol narcolepsy thinking thank youherriot tabuteau chief executive officer sure couple question around branding pricing product let ari provide color thinking two thing preview saying obviously thinking option would able comment much make final determination relates ax narcolepsy nda timing gating factor longterm safety extension trial monitoring enrolling need complete readout order complete package ndaari maizel executive vice president head commercial yes thanks question regarding branding pricing dynamic ax currently performing analysis better understand potential impact brand different brand lot consideration go including ensuring clarity around patient dosing administration potential halo effect associated multiple indication fact comorbid depression roughly alzheimers patient lot consideration share detail future regarding reboxetine pricing another area analysis currently exploring share additional detail futuredavid amsellem piper sandler analyst thank youoperatorthank next question today coming joseph thome td cowen line livejoe thome td cowen analyst hi good morning thanks taking question maybe first one ax know ax study really powered cataplexy little unclear going actually get sleepiness score talk little bit clinician perspective important also see signal sleepiness addition cataplexy kind come another therapeutic like sunosi address sleepiness component second sunosi mdd thinking timeline data remember gemini took six month first patient dose actually seeing data possible could see sunosi mdd data year kind main difference gemini study would make potentially case thank youherriot tabuteau chief executive officer thanks question regard ax close data readout refrain making comment around look close know soon profile phase trial think product favorable placement treatment paradigm complement solriamfetol treatment option looking forward data readout provide u first phase data complement phase data generated thus far term sunosi regard mdd say hopefully announce enrollment first patient study remains track start quarterjoe thome td cowen analyst ok thank youoperatorthank operator instruction next question coming marc goodman leerink partner line livemarc goodman leerink partner analyst yes good morning nick talk thinking spending year secondly talked enough cash get cash flow positivity give u sense secondly herriot willing give u sense percent ad agitation study enrolled maybe give u sense thanksnick pizzie chief financial officer sure yes thanks marc rd expense quarter million million q ticked slightly previous quarter expect rd spend increase gradually solriamfetol phase trial commenced year increase also offset though lower clinical cost symphony advance focus trial complete also ax ax ndas filed sga line total expense quarter million also slight increase previous quarter know mentioned biggest increase sga due sale force expansion took place throughout q expansion occurred throughout quarter roughly half quarter expense expansion realized q would expect slight increase q realize full burden expansion cash flow positivity profitability still early stage auvelity launch bit year removed acquisition sunosi modeled various scenario based success thus far feel confident ability cash flow positive aware launch nature volatile provided guidance specific timeline cash flow positivity herriot want take next questionherriot tabuteau chief executive officer yes thanks marc question provided specific percentage enrollment trial lately however weigh agitation confident able result yearoperatorthank next question coming graig suvannavejh mizuho security line live graig line live perhaps phone mutegraig suvannavejh mizuho security analyst hear meoperatoryes please go aheadgraig suvannavejh mizuho security analyst ok great thanks sorry congrats quarter two question one comment auvelity dtc effort thought around effort might evolve level satisfaction done far needed goforward basis secondly think potential solriamfetol mdd could remind u think differential positioning product auvelity thanksari maizel executive vice president head commercial hey graig thanks much ari appreciate question know dtc effort today largely focused digital engagement pleased investment far observed market research nearly eight patient ask auvelity receive optimistic continued investment consumer advertising assessing additional investment moment would expect share update later year based whether intend increase investment around consumer advertising relates solriamfetol mdd know mdd highly heterogeneous condition patient respond type treatment overlapping symptom illness particular symptom may difficult patient others usually room multiple treatment option help patient data around solriamfetol mdd little premature talk copositioning auvelity based experience space believe opportunity product help patient achieve meaningful symptom reliefgraig suvannavejh mizuho security analyst thank youoperatorthank next question coming david hoang citigroup line livedavid hoang citi analyst hi good morning thanks taking question congrats quarter maybe two first auvelity could provide color around ongoing payer discussion commercial channel expectation improve coverage current think covered life regarding solriamfetol adhd result focus study hand else would needed proceed snda filing result positive thanks muchherriot tabuteau chief executive officer sure take question reverse order solriamfetol focus study adult wanting phase trial pediatric population study patient population needed nda filingari maizel executive vice president head commercial yes related payer discussion mentioned roughly coverage commercial channel overall across channel way think payer dynamic taking disciplined approach contracting preserve longterm profitability product however anticipate expanding coverage time remain actively engaged health insurer improve access insured patient mention current investment patient saving program well reimbursement service support continued prescription growth current level coverage mentioned remains life auvelityoperatorthank next question coming myles minter william blair line livemyles minter william blair company analyst hey thanks taking question teva anda filing know active noticed recently got new ip listed fda orange book patent expires got chapter filing patent might aware secondly back coverage commercial channel flat quarter quarter yet conversation progressing sticking point major payer yet get online auvelity moment formulary positioning risk benefit simply coming price thankshunter murdock general counsel yes thank question hunter murdock yes patent going paragraph filing filed suit public information three paragraph certification relating patent teva litigationari maizel executive vice president head commercial ari regarding comment yes stable quarter quarter every payer discussion different case related ultimate price case related utilization management parameter progressing conversation meaningful discussion take time ongoing negotiation hopefully able share update next quartermyles minter william blair company analyst ok thanks question congrats yearoperatorthank next question today coming yatin suneja guggenheim security line liveeddie hickman guggenheim partner analyst hey guy thanks taking question eddie yatin morning regarding brexpiprazole increase longterm care channel since ada approval good comp auvelity launch could inflect upon approval different safety profile blackbox warning make auvelity attractive option population additional commercial infrastructure would need see kind inflection like brexpiprazole saw approved thanksari maizel executive vice president head commercial yes thanks question one clarification data suggest increasing brexpiprazole longterm care medicare channel think additional data would needed understand whether longterm care setting outpatient think little premature suggest good analog ax product different clinical profile ax nonatypical antipsychotic slightly different profile overall expect meaningful growth within indication approved outpatient setting well longterm care herriot suggested earlier trial focused outpatient setting hope delay patient going long term care facility term commercial infrastructure obviously evaluating sale force size structure relative overall pipeline expect meaningful presence longterm care facility however existing sale force primarily focused outpatient care practice expect continue even ada detail come feel confident able efficient selling effort based shared call point indication exist pipeline well onmarket productseddie hickman guggenheim partner analyst great thanks congrats againoperatorthank time question two analyst next question coming matt kaplan ladenburg thalmann line livematt kaplan ladenburg thalmann company analyst hi thanks taking question good morning guy maybe question ari term completed sale force expansion start see impact new sale force guess course year really first half second half start see gaining tractionari maizel executive vice president head commercial yes thank question expect see ramp term impact course year obviously majority expansion representative hired late last year completed training january year take time go call cycle build confidence brand story messaging also expand reach primary care setting expect bill occur course year starting see meaningful impact term call activity would expect demand trend corresponding increase course yearmatt kaplan ladenburg thalmann company analyst ok helpful maybe question herriot gave added detail term necessary filing snda adhd term indication pursuing phase iii solriamfetol mdd binge eating disorder shift work would necessary include two phase trial could oneherriot tabuteau chief executive officer sure regard solriamfetol mdd anticipate need two phase trial launching first phase trial know quarter binge eating disorder similarly anticipate would need two phase trial also track launch first phase trial quarter shift work disorder need one phase trial file sndamatt kaplan ladenburg thalmann company analyst right well thanks taking questionsoperatorthank final question today coming vikram purohit morgan stanley line live vikram perhaps phone mutevikram purohit morgan stanley analyst hi good morning hear meoperatorplease proceedherriot tabuteau chief executive officer yesvikram purohit morgan stanley analyst thank good morning thanks taking question two commercial question one ada one mdd ada assuming advance positive ax approved indication would expect annual duration therapy setting given potential difference number duration agitation episode patient ad experience secondly mdd think auvelity sale guidance possibility year metric aspect launch monitoring gauge whether guidance reasonable provide thanksherriot tabuteau chief executive officer thanks question regard duration treatment alzheimers disease agitation alzheimers disease agitation viewed chronic condition studying also reflective fda think feedback gotten know longterm openlabel safety extension trial ongoing patient drug fairly long time study oneyear trialnick pizzie chief financial officer yes sure vikram nick relates sale guidance given relatively short period time since launch evolving dynamic including increase sale force effort well variability market access ready provide forwardlooking guidance sale likely case entirety pointvikram purohit morgan stanley analyst got thank youoperatorthank reached end questionand answer session would like turn floor back management closing commentsherriot tabuteau chief executive officer well thank taking time join u today quarterly update strong year axsome entered growing commercial business latestage neuroscience pipeline encompasses five innovative product candidate development serious neuropsychiatry indication look forward providing multiple update throughout year progress thank great rest dayoperatoroperator signoff duration minutescall participantsmark jacobson chief operating officerherriot tabuteau chief executive officernick pizzie chief financial officerari maizel executive vice president head commercialleonid timashev rbc capital market analystcharles duncan cantor fitzgerald analystash verma ubs analystasim rana truist security analystjason gerberry bank america merrill lynch analystdavid amsellem piper sandler analystjoe thome td cowen analystmarc goodman leerink partner analystgraig suvannavejh mizuho security analystdavid hoang citi analystmyles minter william blair company analysthunter murdock general counseleddie hickman guggenheim partner analystmatt kaplan ladenburg thalmann company analystvikram purohit morgan stanley analyst axsm analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool position recommends axsome therapeutic motley fool disclosure policy